PMID- 21087958
OWN - NLM
STAT- MEDLINE
DCOM- 20110811
LR  - 20220317
IS  - 1552-5783 (Electronic)
IS  - 0146-0404 (Linking)
VI  - 52
IP  - 6
DP  - 2011 May 18
TI  - Predictors of short-term visual outcome after anti-VEGF therapy of macular edema 
      due to central retinal vein occlusion.
PG  - 3334-7
LID - 10.1167/iovs.10-6097 [doi]
AB  - PURPOSE: The purpose of this study was to analyze predictive factors for 
      best-corrected visual acuity (BCVA) after anti-VEGF treatment in patients with 
      macular edema (ME) secondary to central retinal vein occlusion (CRVO). METHODS: 
      This prospective study enrolled treatment-naive patients with ME secondary to 
      CRVO. BCVA, ophthalmoscopy, fundus photography, and spectral domain optical 
      coherence tomography (SD-OCT) imaging were performed. SD-OCT was analyzed for 
      integrity of the external limiting membrane (ELM), photoreceptor inner segments 
      (IS), and outer segments (OS). Patients were treated with intravitreal 
      bevacizumab (1.25 mg) or ranibizumab (0.5 mg). BCVA outcome was analyzed 4 weeks 
      after the first injection. RESULTS: Sixty-two eyes of 62 patients (39 men, 23 
      women; mean age: 67 +/-16 years) were included. In 55%, the ELM was intact. These 
      eyes also showed intact photoreceptor IS/OS in horizontal and vertical single 
      scans. Disturbed ELM was seen in 45% and was accompanied by focal disintegration 
      of IS/OS. Four weeks after injection, 58% showed clinically relevant increases of 
      BCVA (>/=5 letters). Mean BCVA ranged from 20 to 86 letters. The mean BCVA increase 
      was 18 +/- 12 letters in eyes with intact ELM compared with 4 +/- 10 letters with 
      disturbed ELM (P < 0.001). CONCLUSIONS: Depending on the integrity of the outer 
      retinal layers, the authors observed rapid and clinically relevant improvement in 
      BCVA after the first anti-VEGF injection. In the development of an optimal 
      treatment regime, the indication for treatment and re-treatment should be based 
      on functional and morphologic findings, such as the deterioration of outer 
      retinal layers. Intact ELM in SD-OCT imaging is associated with better visual 
      outcomes after intravitreal anti-VEGF treatment in patients with ME secondary to 
      CRVO.
FAU - Wolf-Schnurrbusch, Ute E K
AU  - Wolf-Schnurrbusch UE
AD  - Universitatsklinik fur Augenheilkunde, Bern, Switzerland. ute.wolf@insel.ch
FAU - Ghanem, Ramzi
AU  - Ghanem R
FAU - Rothenbuehler, Simon P
AU  - Rothenbuehler SP
FAU - Enzmann, Volker
AU  - Enzmann V
FAU - Framme, Carsten
AU  - Framme C
FAU - Wolf, Sebastian
AU  - Wolf S
LA  - eng
SI  - ClinicalTrials.gov/NCT00564291
PT  - Clinical Trial
PT  - Journal Article
DEP - 20110518
PL  - United States
TA  - Invest Ophthalmol Vis Sci
JT  - Investigative ophthalmology & visual science
JID - 7703701
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (VEGFA protein, human)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 2S9ZZM9Q9V (Bevacizumab)
RN  - ZL1R02VT79 (Ranibizumab)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Angiogenesis Inhibitors/*therapeutic use
MH  - Antibodies, Monoclonal/therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Bevacizumab
MH  - Epiretinal Membrane/pathology
MH  - Female
MH  - Fluorescein Angiography
MH  - Humans
MH  - Intravitreal Injections
MH  - Macular Edema/*drug therapy/etiology/physiopathology
MH  - Male
MH  - Middle Aged
MH  - Ophthalmoscopy
MH  - Photoreceptor Cells, Vertebrate/pathology
MH  - Prospective Studies
MH  - Ranibizumab
MH  - Retinal Vein Occlusion/*complications/physiopathology
MH  - Tomography, Optical Coherence
MH  - Treatment Outcome
MH  - Vascular Endothelial Growth Factor A/*antagonists & inhibitors
MH  - Visual Acuity/*physiology
MH  - Young Adult
EDAT- 2010/11/23 06:00
MHDA- 2011/08/13 06:00
CRDT- 2010/11/20 06:00
PHST- 2010/11/20 06:00 [entrez]
PHST- 2010/11/23 06:00 [pubmed]
PHST- 2011/08/13 06:00 [medline]
AID - iovs.10-6097 [pii]
AID - 10.1167/iovs.10-6097 [doi]
PST - epublish
SO  - Invest Ophthalmol Vis Sci. 2011 May 18;52(6):3334-7. doi: 10.1167/iovs.10-6097.